1609581-27-2

Upstream product

• 31270-80-1 4-chlorofuro[3,2-c]pyridine 
• 14472-14-1 4-bromo-3-methylphenol 
• 1609581-00-1 4-(4-bromo-3-methylphenoxy)furo[3,2-c]pyridine 
• 1609581-25-0 4-[4-bromo-3-(bromomethyl)phenoxy]furo[3,2-c]pyridine 
• 1609581-26-1 [2-bromo-5-(furo[3,2-c]pyridin-4-yloxy)phenyl]methanol 
• 75-36-5 acetyl chloride 

Downstream Products

• 1609581-28-3 5-(furo[3,2-c]pyridin-4-yloxy)-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzyl acetate 
• 1609577-41-4 [2-(4,6-dimethylpyrimidin-5-yl)-5-(furo[3,2-c]pyridin-4-yloxy)phenyl]methanol 
• 1609577-43-6 4-[4-(4,6-dimethylpyrimidin-5-yl)-3-(fluoromethyl)phenoxy]furo[3,2-c]pyridine 
• 1609581-29-4 2-(4,6-dimethylpyrimidin-5-yl)-5-(furo[3,2-c]pyridin-4-yloxy)benzyl acetate 

Relevant academic research and scientific papers

IMAGING AGENTS

The present invention relates to radiolabelled 4-(furo[3,2-c]pyridin-4-yl) derivatives and their use as radioactive tracers, and in particular their use as imaging agents.

HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS

The present invention provides, in part, compounds of Formula I: and pharmaceutically acceptable salts thereof and N-oxides thereof; processes and intermediates for preparation of; and compositions and uses thereof. The present invention further provides D1 agonists with reduced D1R desensitization, D1 agonists with a reduced β- arrestin recruitment activity relative to Dopamine, D1 agonists interacting significantly with the Ser188 but not significantly with the Ser202 of a D1R when binding to the D1R, D1 agonists interacting less strongly with the Asp103 and interacting less strongly with the Ser198 of a D1R when binding to the D1R, and their uses.